2021
DOI: 10.3390/pathogens10060727
|View full text |Cite
|
Sign up to set email alerts
|

Streptococcus Pneumoniae-Associated Hemolytic Uremic Syndrome in the Era of Pneumococcal Vaccine

Abstract: Streptococcus pneumoniae-associated hemolytic uremic syndrome (Sp-HUS) is a serious complication of invasive pneumococcal disease that is associated with increased mortality in the acute phase and morbidity in the long term. Recently, Sp-HUS definition has undergone revision and cases are categorized as definite, probable, and possible, based on less invasive serological investigations that evaluate Thomsen-Friedenreich crypt antigen (T-antigen) activation. In comparison to the pre-vaccine era, Sp-HUS incidenc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(5 citation statements)
references
References 108 publications
0
5
0
Order By: Relevance
“…This difference could be attributed to the inherently higher virulence and invasiveness of pneumococcal infections, which often result in more extensive pulmonary involvement and systemic complications, thereby necessitating a more prolonged and intensive approach to respiratory support that is typically required for patients with Shiga-toxin-producing HUS. [8][9][10][11][12][13][14][15] Prolonged MV in children is of importance as there can be significant associated morbidity and mortality. Younger age, black race, pneumonia, pneumothorax, liver dysfunction, ileus with perforation, presence of pneumococcal disease, and sepsis were independent risk factors for prolonged MV utilization in our study.…”
Section: Discussionmentioning
confidence: 99%
“…This difference could be attributed to the inherently higher virulence and invasiveness of pneumococcal infections, which often result in more extensive pulmonary involvement and systemic complications, thereby necessitating a more prolonged and intensive approach to respiratory support that is typically required for patients with Shiga-toxin-producing HUS. [8][9][10][11][12][13][14][15] Prolonged MV in children is of importance as there can be significant associated morbidity and mortality. Younger age, black race, pneumonia, pneumothorax, liver dysfunction, ileus with perforation, presence of pneumococcal disease, and sepsis were independent risk factors for prolonged MV utilization in our study.…”
Section: Discussionmentioning
confidence: 99%
“…Pneumococcal serotypes are defined by the biochemical structure of their polysaccharide capsule; they are of greatest relevance in the rollout of infection and more than 100 serotypes have been described to date ( 72 ). The prominent serotypes of Sp-HUS, before the introduction of the pneumococcal vaccine, were 3, 6B, 8, 9V, 14, 19, and 23F ( 5 ). Soon after the introduction of the 7- and 13-valent pneumococcal protein conjugate vaccines in 2000 and 2010, respectively, there was a shift of Sp-HUS-associated serotypes to those that were not covered by the vaccines.…”
Section: Discussionmentioning
confidence: 99%
“…However, the pathophysiology of the infection-associated form of HUS remains largely unclear ( 4 ). In around 90% of cases, an infection-related HUS is caused by Shiga-like toxin-producing bacteria, such as enterohemorrhagic Escherichia coli (EHEC) or Shigella dysenteriae type 1 ( 5 ). Sp-HUS accounts for approximately 5% of all HUS cases and occurs mainly among children under 2 years old, and the predicted mortality rate is 12.3% ( 6 , 7 ).…”
Section: Introductionmentioning
confidence: 99%
“…Pneumococcal serotypes are defined by the biochemical structure of their polysaccharide capsule; they are of greatest relevance in the rollout of infection and more than 100 serotypes have been described to date(74). The prominent serotypes of Sp-HUS, before the introduction of the pneumococcal vaccine, were 3, 6B, 8, 9V, 14, 19, and 23F(5). Soon after the introduction of the 7- and 13-valent pneumococcal protein conjugate vaccines in 2000 and 2010, respectively, there was a shift of Sp-HUS-associated serotypes to those that were not covered by the vaccines.…”
Section: Discussionmentioning
confidence: 99%
“…However, the pathophysiology of the infection-associated form of HUS remains largely unclear (4). In around 90% of cases, an infection-related HUS is caused by Shiga-like toxin-producing bacteria, such as enterohaemorrhagic Escherichia coli (STEC) or Shigella dysenteriae type 1 (5). Sp-HUS accounts for approximately 5% of all HUS cases and occurs mainly among children under 2 years old, and the predicted mortality rate is 12.3% (6,7).…”
Section: Introductionmentioning
confidence: 99%